Cardio-rheumatology: present and future. Part II

Cover Page


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Patients with rheumatic diseases exhibit a markedly increased risk of developing and accelerating cardiovascular pathology, which is largely attributed to the significant role of chronic inflammation as one of the etiological factors in both atherogenesis and heart failure. Achieving sustained clinical and laboratory remission of the Immune-mediated inflammatory disease has been shown to reduce the risk of cardiovascular complications. Given the direct association between persistent inflammation and a wide range of comorbid conditions, this factor must be carefully considered when planning and implementing rational pharmacotherapy in multimorbid patients.

It is well established that pharmacological agents used in rheumatology exert diverse effects on the cardiovascular system. Over the past decade, growing research interest has been directed toward the potential application of anti-inflammatory agents with different mechanisms of action for both the prevention and treatment of atherosclerosis and ischemic heart disease. Particular attention has been paid to the modulation of the “NLRP3 inflammasome – interleukin-1 – interleukin-6 – C-reactive protein” signaling pathway. According to several studies, inhibition of this cascade may contribute to reduced likelihood of cardiovascular events.

This review summarizes current data on the effects of various classes of antirheumatic drugs on the cardiovascular system, including both their beneficial and adverse effects.

Full Text

Restricted Access

About the authors

Yi Ma

Third Xiangya Hospital of the Central South University

Email: mayi2908@yandex.ru
ORCID iD: 0000-0002-2339-4263

MD, Cand. Sci. (Medicine)

China, Changsha

Zhuo Wang

Third Xiangya Hospital of the Central South University

Email: wangzhuo1008@yandex.ru
ORCID iD: 0000-0002-2415-4982

MD, Cand. Sci. (Medicine)

China, Changsha

Vadim I. Mazurov

North-Western State Medical University named after I.I. Mechnikov; Clinical Rheumatology Hospital No. 25

Email: maz.nwgmu@yandex.ru
ORCID iD: 0000-0002-0797-2051
SPIN-code: 6823-5482

MD, Dr. Sci. (Medicine), Professor, Academician of the RAS, Honored Scientist of the Russian Federation

Russian Federation, Saint Petersburg; Saint Petersburg; Saint Petersburg; Saint Petersburg

Evgeniy A. Trofimov

North-Western State Medical University named after I.I. Mechnikov

Email: evgeniy.trofimov@szgmu.ru
ORCID iD: 0000-0003-3236-4485
SPIN-code: 4358-1663

MD, Dr. Sci. (Medicine)

Russian Federation, Saint Petersburg

Roman A. Bashkinov

North-Western State Medical University named after I.I. Mechnikov; Clinical Rheumatology Hospital No. 25

Author for correspondence.
Email: bashkinov-roman@mail.ru
ORCID iD: 0000-0001-9344-1304
SPIN-code: 5169-5066

MD

Russian Federation, 41 Kirochnaya St., Saint Petersburg, 191015; Saint Petersburg

References

  1. Alfaddagh A, Martin SS, Leucker TM, et al. Inflammation and cardiovascular disease: From mechanisms to therapeutics. Am J Prev Cardiol. 2020;4:100130. doi: 10.1016/j.ajpc.2020.100130
  2. Ridker PM. Anticytokine agents: Targeting interleukin signaling pathways for the treatment of atherothrombosis. Circ Res. 2019;124(3):437–450. doi: 10.1161/CIRCRESAHA.118.313129
  3. Miyamoto T, Carrero JJ, Stenvinkel P. Inflammation as a risk factor and target for therapy in chronic kidney disease. Curr Opin Nephrol Hypertens. 2011;20(6):662–668. doi: 10.1097/MNH.0b013e32834ad504
  4. Shirazi LF, Bissett J, Romeo F, Mehta JL. Role of inflammation in heart failure. Curr Atheroscler Rep. 2017;19(6):27. doi: 10.1007/s11883-017-0660-3
  5. Libby P. Inflammation and cardiovascular disease mechanisms. Am J Clin Nutr. 2006;83(2):456S–460S. doi: 10.1093/ajcn/83.2.456S
  6. Prasad M, Hermann J, Gabriel SE, et al. Cardiorheumatology: cardiac involvement in systemic rheumatic disease. Nat Rev Cardiol. 2015;12(3):168–176. doi: 10.1038/nrcardio.2014.206
  7. Lutgens E, Atzler D, Döring Y, et al. Immunotherapy for cardiovascular disease. Eur Heart J. 2019;40(48):3937–3946. doi: 10.1093/eurheartj/ehz283
  8. Ridker PM. From C-reactive protein to Interleukin-6 to Interleukin-1: Moving upstream to identify novel targets for atheroprotection. Circ Res. 2016;118(1):145–156. doi: 10.1161/CIRCRESAHA.115.306656
  9. Jin Y, Fu J. Novel insights into the NLRP 3 inflammasome in atherosclerosis. J Am Heart Assoc. 2019;8(12):e012219. doi: 10.1161/JAHA.119.012219
  10. Catapano AL, Graham I, De Backer G, et al. 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias. Eur Heart J. 2016;37(39):2999–3058. doi: 10.1093/eurheartj/ehw272
  11. Bohula EA, Giugliano RP, Cannon CP, et al. Achievement of dual low-density lipoprotein cholesterol and high-sensitivity C-reactive protein targets more frequent with the addition of ezetimibe to simvastatin and associated with better outcomes in IMPROVE-IT. Circulation. 2015;132(13):1224–1233. doi: 10.1161/CIRCULATIONAHA.115.018381
  12. Ridker PM, Danielson E, Fonseca FA, et al. Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial. Lancet. 2009;373(9670):1175–1182. doi: 10.1016/S0140-6736(09)60447-5
  13. Ridker PM, Danielson E, Fonseca FA, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359(21):2195–2207. doi: 10.1056/NEJMoa0807646
  14. Antonopoulos AS, Margaritis M, Lee R, et al. Statins as anti-inflammatory agents in atherogenesis: molecular mechanisms and lessons from the recent clinical trials. Curr Pharm Des. 2012;18(11):1519–1530. doi: 10.2174/138161212799504803
  15. Ortego M, Bustos C, Hernández-Presa MA, et al. Atorvastatin reduces NF-kappaB activation and chemokine expression in vascular smooth muscle cells and mononuclear cells. Atherosclerosis. 1999;147(2):253–261. doi: 10.1016/s0021-9150(99)00193-8
  16. Garlichs CD, John S, Schmeisser A, et al. Upregulation of CD40 and CD40 ligand (CD154) in patients with moderate hypercholesterolemia. Circulation. 2001;104(20):2395–2400. doi: 10.1161/hc4501.099312
  17. Barnabe C, Martin BJ, Ghali WA. Systematic review and meta-analysis: anti-tumor necrosis factor α therapy and cardiovascular events in rheumatoid arthritis. Arthritis Care Res (Hoboken). 2011;63(4):522529. doi: 10.1002/acr.20371
  18. Micha R, Imamura F, Wyler von Ballmoos M, et al. Systematic review and meta-analysis of methotrexate use and risk of cardiovascular disease. Am J Cardiol. 2011;108(9):1362–1370. doi: 10.1016/j.amjcard.2011.06.054
  19. Ridker PM, Everett BM, Thuren T, et al. Antiinflammatory therapy with canakinumab for atherosclerotic disease. N Engl J Med. 2017;377(12):1119–1131. doi: 10.1056/NEJMoa1707914
  20. Nidorf SM, Eikelboom JW, Budgeon CA, Thompson PL. Low-dose colchicine for secondary prevention of cardiovascular disease. J Am Coll Cardiol. 2013;61(4):404–410. doi: 10.1016/j.jacc.2012.10.027
  21. Nidorf SM, Fiolet ATL, Mosterd A, et al. Colchicine in patients with chronic coronary disease. N Engl J Med. 2020;383(19):1838–1847. doi: 10.1056/NEJMoa2021372
  22. Tardif JC, Kouz S, Waters DD, et al. Efficacy and safety of low-dose colchicine after myocardial infarction. N Engl J Med. 2019;381(26):2497–2505. doi: 10.1056/NEJMoa1912388
  23. Samuel M, Tardif JC, Bouabdallaoui N, et al. Colchicine for secondary prevention of cardiovascular disease: a systematic review and meta-analysis of randomized controlled trials. Can J Cardiol. 2021;37(5):776–785. doi: 10.1016/j.cjca.2020.10.006
  24. Casula M, Andreis A, Avondo S, et al. Colchicine for cardiovascular medicine: a systematic review and meta-analysis. Future Cardiol. 2022;18(8):647–659. doi: 10.2217/fca-2020-0206
  25. Ridker PM, Devalaraja M, Baeres FMM, et al. IL-6 inhibition with ziltivekimab in patients at high atherosclerotic risk (RESCUE): a double-blind, randomised, placebo-controlled, phase 2 trial. Lancet. 2021;397(10289):2060–2069. doi: 10.1016/S0140-6736(21)00520-1
  26. Wada Y, Jensen C, Meyer ASP, et al. Efficacy and safety of interleukin-6 inhibition with ziltivekimab in patients at high risk of atherosclerotic events in Japan (RESCUE-2): A randomized, double-blind, placebo-controlled, phase 2 trial. J Cardiol. 2023;82(4):279–285. doi: 10.1016/j.jjcc.2023.05.006
  27. Mazurov VI, Lesnyak OM, editors. Rheumatology. Pharmacotherapy without errors. Moscow: E-noto; 2017. 528 p. (In Russ.)
  28. Antman EM, Bennett JS, Daugherty A, et al. Use of nonsteroidal antiinflammatory drugs: an update for clinicians: a scientific statement from the American Heart Association. Circulation. 2007;115(12):1634–1642. doi: 10.1161/CIRCULATIONAHA.106.181424
  29. Topper JN, Cai J, Falb D, Gimbrone MA Jr. Identification of vascular endothelial genes differentially responsive to fluid mechanical stimuli: cyclooxygenase-2, manganese superoxide dismutase, and endothelial cell nitric oxide synthase are selectively up-regulated by steady laminar shear stress. Proc Natl Acad Sci U S A. 1996;93(19):10417–10422. doi: 10.1073/pnas.93.19.10417
  30. Bolli R, Shinmura K, Tang XL, et al. Discovery of a new function of cyclooxygenase (COX)-2: COX-2 is a cardioprotective protein that alleviates ischemia/reperfusion injury and mediates the late phase of preconditioning. Cardiovasc Res. 2002;55(3):506–519. doi: 10.1016/s0008-6363(02)00414-5
  31. Leonova MV. Cardiotoxicity of non-steroid anti-inflammatory drugs. Consilium Medicum. 2019;21(10):107–116. EDN: DVVPVO doi: 10.26442/20751753.2019.10.190191
  32. McGettigan P, Henry D. Cardiovascular risk with non-steroidal anti-inflammatory drugs: systematic review of population-based controlled observational studies. PLoS Med. 2011;8(9):e1001098. doi: 10.1371/journal.pmed.1001098
  33. Coxib and traditional NSAID Trialists’ (CNT) Collaboration, Bhala N, Emberson J, et al. Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials. Lancet. 2013;382(9894):769–779. doi: 10.1016/S0140-6736(13)60900-9
  34. Schjerning Olsen AM, Fosbøl EL, Lindhardsen J, et al. Duration of treatment with nonsteroidal anti-inflammatory drugs and impact on risk of death and recurrent myocardial infarction in patients with prior myocardial infarction: a nationwide cohort study. Circulation. 2011;123(20):2226–2235. doi: 10.1161/CIRCULATIONAHA.110.004671
  35. Schjerning AM, McGettigan P, Gislason G. Cardiovascular effects and safety of (non-aspirin) NSAIDs. Nat Rev Cardiol. 2020;17(9):574–584. doi: 10.1038/s41569-020-0366-z
  36. Grosser T, Fries S, FitzGerald GA. Biological basis for the cardiovascular consequences of COX-2 inhibition: therapeutic challenges and opportunities. J Clin Invest. 2006;116(1):4–15. doi: 10.1172/JCI27291
  37. Arutyunov GP, Paleev FN, Tarlovskaya EI, et al. Pericarditis. Clinical Guidelines 2022. Russian Journal of Cardiology. 2023;28(3):107–167. EDN: QMPQPU doi: 10.15829/1560-4071-2023-5398
  38. Adler Y, Charron P, Imazio M, et al. 2015 ESC Guidelines for the diagnosis and management of pericardial diseases: The Task Force for the Diagnosis and Management of Pericardial Diseases of the European Society of Cardiology (ESC)Endorsed by: The European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2015;36(42):2921–2964. doi: 10.1093/eurheartj/ehv318
  39. Meara AS, Simon LS. Advice from professional societies: appropriate use of NSAIDs. Pain Med. 2013;14 Suppl 1:S3–S10. doi: 10.1111/pme.12282
  40. Verhoeven F, Prati C, Maguin-Gaté K, et al. Glucocorticoids and endothelial function in inflammatory diseases: focus on rheumatoid arthritis. Arthritis Res Ther. 2016;18(1):258. doi: 10.1186/s13075-016-1157-0
  41. Roubille C, Richer V, Starnino T, et al. The effects of tumour necrosis factor inhibitors, methotrexate, non-steroidal anti-inflammatory drugs and corticosteroids on cardiovascular events in rheumatoid arthritis, psoriasis and psoriatic arthritis: a systematic review and meta-analysis. Ann Rheum Dis. 2015;74(3):480–489. doi: 10.1136/annrheumdis-2014-206624
  42. Deng HW, Mei WY, Xu Q, et al. The role of glucocorticoids in increasing cardiovascular risk. Front Cardiovasc Med. 2023;10:1187100. doi: 10.3389/fcvm.2023.1187100
  43. Atzeni F, Rodríguez-Carrio J, Popa CD, et al. Cardiovascular effects of approved drugs for rheumatoid arthritis. Nat Rev Rheumatol. 2021;17(5):270–290. doi: 10.1038/s41584-021-00593-3
  44. Peters MJ, Symmons DP, McCarey D, et al. EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis. Ann Rheum Dis. 2010;69(2):325–331. doi: 10.1136/ard.2009.113696
  45. Agca R, Heslinga SC, Rollefstad S, et al. EULAR recommendations for cardiovascular disease risk management in patients with rheumatoid arthritis and other forms of inflammatory joint disorders: 2015/2016 update. Ann Rheum Dis. 2017;76(1):17–28. doi: 10.1136/annrheumdis-2016-209775
  46. Arutyunov GP, Paleev FN, Moiseeva OM, et al. 2020 Clinical practice guidelines for myocarditis in adults. Russian Journal of Cardiology. 2021;26(11):136–182. EDN: SWZXVO doi: 10.15829/1560-4071-2021-4790
  47. Bäck M, Hansson GK. Anti-inflammatory therapies for atherosclerosis. Nat Rev Cardiol. 2015;12(4):199–211. doi: 10.1038/nrcardio.2015.5
  48. Bulgarelli A, Martins Dias AA, Caramelli B, Maranhão RC. Treatment with methotrexate inhibits atherogenesis in cholesterol-fed rabbits. J Cardiovasc Pharmacol. 2012;59(4):308–314. doi: 10.1097/FJC.0b013e318241c385
  49. Westlake SL, Colebatch AN, Baird J, et al. The effect of methotrexate on cardiovascular disease in patients with rheumatoid arthritis: a systematic literature review. Rheumatology (Oxford). 2010;49(2):295–307. doi: 10.1093/rheumatology/kep366
  50. Ridker PM, Everett BM, Pradhan A, et al. Low-dose methotrexate for the prevention of atherosclerotic events. N Engl J Med. 2019;380(8):752–762. doi: 10.1056/NEJMoa1809798
  51. Deftereos SG, Beerkens FJ, Shah B, et al. colchicine in cardiovascular disease: in-depth review. Circulation. 2022;145(1):61–78. doi: 10.1161/CIRCULATIONAHA.121.056171
  52. Tong DC, Quinn S, Nasis A, et al. Colchicine in patients with acute coronary syndrome: the Australian COPS randomized clinical trial. Circulation. 2020;142(20):1890–1900. doi: 10.1161/CIRCULATIONAHA.120.050771
  53. Mewton N, Roubille F, Bresson D, et al. Effect of colchicine on myocardial injury in acute myocardial infarction. Circulation. 2021;144(11):859–869. doi: 10.1161/CIRCULATIONAHA.121.056177
  54. Fiolet ATL, Opstal TSJ, Mosterd A, et al. Efficacy and safety of low-dose colchicine in patients with coronary disease: a systematic review and meta-analysis of randomized trials. Eur Heart J. 2021;42(28):2765–2775. doi: 10.1093/eurheartj/ehab115
  55. Deftereos S, Giannopoulos G, Panagopoulou V, et al. Anti-inflammatory treatment with colchicine in stable chronic heart failure: a prospective, randomized study. JACC Heart Fail. 2014;2(2):131–137. doi: 10.1016/j.jchf.2013.11.006
  56. Hemkens LG, Ewald H, Gloy VL, et al. Colchicine for prevention of cardiovascular events. Cochrane Database Syst Rev. 2016;2016(1):CD011047. doi: 10.1002/14651858.CD011047.pub2
  57. Boytsov SA, Pogosova NV, Ansheles AA, et al. Cardiovascular prevention 2022. Russian national guidelines. Russian Journal of Cardiology. 2023;28(5):119–249. EDN: EUDWYG doi: 10.15829/1560-4071-2023-5452
  58. Mazurov VI, Bashkinov RA, Gaidukova IZ, Fonturenko AYu. The effect of asymptomatic hyperuricemia on comorbidities and the possibility of its correction. Russian Medical Inquiry. 2021;29(7):24–30. EDN: EZWQOO
  59. Drapkina OM, Mazurov VI, Martynov AI, et al. “Focus on hyperuricemia”. The resolution of the Expert Council. Cardiovascular Therapy and Prevention. 2023;22(4):77–84. EDN: KRCKAU doi: 10.15829/1728-8800-2023-3564
  60. Chazova IE, Zhernakova YuV, Kislyak OA, et al. Consensus on patients with hyperuricemia and high cardiovascular risk treatment: 2022. Systemic Hypertension. 2022;19(1):5–22. EDN: HBLVVV doi: 10.38109/2075-082X-2022-1-5-22
  61. Borghi C, Domienik-Karłowicz J, Tykarski A, et al. Expert consensus for the diagnosis and treatment of patient with hyperuricemia and high cardiovascular risk: 2021 update. Cardiol J. 2021;28(1):1–14. doi: 10.5603/CJ.a2021.0001
  62. Drapkina OM, Mazurov VI, Martynov AI, et al. Consensus statement on the management of patients with asymptomatic hyperuricemia in general medical practice. Cardiovascular Therapy and Prevention. 2024;23(1):89–104. EDN: WXKMIG doi: 10.15829/1728-8800-2024-3737
  63. Kushiyama A, Okubo H, Sakoda H, et al. Xanthine oxidoreductase is involved in macrophage foam cell formation and atherosclerosis development. Arterioscler Thromb Vasc Biol. 2012;32(2):291–298. doi: 10.1161/ATVBAHA.111.234559
  64. Rentoukas E, Tsarouhas K, Tsitsimpikou C, et al. The prognostic impact of allopurinol in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention. Int J Cardiol. 2010;145(2):257–258. doi: 10.1016/j.ijcard.2009.08.037
  65. Noman A, Ang DS, Ogston S, et al. Effect of high-dose allopurinol on exercise in patients with chronic stable angina: a randomised, placebo controlled crossover trial. Lancet. 2010;375(9732):2161–2167. doi: 10.1016/S0140-6736(10)60391-1
  66. Rekhraj S, Gandy SJ, Szwejkowski BR, et al. High-dose allopurinol reduces left ventricular mass in patients with ischemic heart disease. J Am Coll Cardiol. 2013;61(9):926–932. doi: 10.1016/j.jacc.2012.09.066
  67. Higgins P, Dawson J, Lees KR, et al. Xanthine oxidase inhibition for the treatment of cardiovascular disease: a systematic review and meta-analysis. Cardiovasc Ther. 2012;30(4):217–226. doi: 10.1111/j.1755-5922.2011.00277.x
  68. Mackenzie IS, Hawkey CJ, Ford I, et al. Allopurinol versus usual care in UK patients with ischaemic heart disease (ALL-HEART): a multicentre, prospective, randomised, open-label, blinded-endpoint trial. Lancet. 2022;400(10359):1195–1205. doi: 10.1016/S0140-6736(22)01657-9
  69. Thanassoulis G, Brophy JM, Richard H, Pilote L. Gout, allopurinol use, and heart failure outcomes. Arch Intern Med. 2010;170(15):1358–1364. doi: 10.1001/archinternmed.2010.198
  70. Hare JM, Mangal B, Brown J, et al. Impact of oxypurinol in patients with symptomatic heart failure. Results of the OPT-CHF study. J Am Coll Cardiol. 2008;51(24):2301–2309. doi: 10.1016/j.jacc.2008.01.068
  71. Givertz MM, Anstrom KJ, Redfield MM, et al. Effects of xanthine oxidase inhibition in hyperuricemic heart failure patients: the xanthine oxidase inhibition for hyperuricemic heart failure patients (EXACT-HF) study. Circulation. 2015;131(20):1763–1771. doi: 10.1161/CIRCULATIONAHA.114.014536
  72. George J, Struthers A. The OPT-CHF (Oxypurinol Therapy for Congestive Heart Failure) trial: a question of dose. J Am Coll Cardiol. 2009;53(25):2405. doi: 10.1016/j.jacc.2008.07.076
  73. Dubreuil M, Zhu Y, Zhang Y, et al. Allopurinol initiation and all-cause mortality in the general population. Ann Rheum Dis. 2015;74(7):1368–1372. doi: 10.1136/annrheumdis-2014-205269
  74. Wei L, Fahey T, Struthers AD, MacDonald TM. Association between allopurinol and mortality in heart failure patients: a long-term follow-up study. Int J Clin Pract. 2009;63(9):1327–1333. doi: 10.1111/j.1742-1241.2009.02118.x
  75. Chinese Society of Endocrinology (2020). Guideline for the Diagnosis and Management of Hyperuricemia and Gout in China (2019). Chin J Endocrinol Metab. 2020;36(1):1–13. doi: 10.3760/cma.j.issn.1000-6699.2020.01.001
  76. Jacobsson LT, Turesson C, Nilsson JA, et al. Treatment with TNF blockers and mortality risk in patients with rheumatoid arthritis. Ann Rheum Dis. 2007;66(5):670–675. doi: 10.1136/ard.2006.062497
  77. Chung ES, Packer M, Lo KH, et al. Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-alpha, in patients with moderate-to-severe heart failure: results of the anti-TNF Therapy Against Congestive Heart Failure (ATTACH) trial. Circulation. 2003;107(25):3133–3140. doi: 10.1161/01.CIR.0000077913.60364.D2
  78. Mann DL, McMurray JJ, Packer M, et al. Targeted anticytokine therapy in patients with chronic heart failure: results of the Randomized Etanercept Worldwide Evaluation (RENEWAL). Circulation. 2004;109(13):1594–1602. doi: 10.1161/01.CIR.0000124490.27666.B2
  79. Everett BM, Cornel JH, Lainscak M, et al. Anti-inflammatory therapy with canakinumab for the prevention of hospitalization for heart failure. Circulation. 2019;139(10):1289–1299. doi: 10.1161/CIRCULATIONAHA.118.038010
  80. Van Tassell BW, Canada J, Carbone S, et al. Interleukin-1 blockade in recently decompensated systolic heart failure: results from REDHART (Recently Decompensated Heart Failure Anakinra Response Trial). Circ Heart Fail. 2017;10(11):e004373. doi: 10.1161/CIRCHEARTFAILURE.117.004373
  81. Abbate A, Trankle CR, Buckley LF, et al. Interleukin-1 blockade inhibits the acute inflammatory response in patients with ST-segment-elevation myocardial infarction. J Am Heart Assoc. 2020;9(5):e014941. doi: 10.1161/JAHA.119.014941
  82. Interleukin-6 receptor mendelian randomisation analysis (IL6R MR) Consortium, Swerdlow DI, Holmes MV, et al. The interleukin-6 receptor as a target for prevention of coronary heart disease: a mendelian randomisation analysis. Lancet. 2012;379(9822):1214–1224. doi: 10.1016/S0140-6736(12)60110-X
  83. Kleveland O, Kunszt G, Bratlie M, et al. Effect of a single dose of the interleukin-6 receptor antagonist tocilizumab on inflammation and troponin T release in patients with non-ST-elevation myocardial infarction: a double-blind, randomized, placebo-controlled phase 2 trial. Eur Heart J. 2016;37(30):2406–2413. doi: 10.1093/eurheartj/ehw171
  84. Singh S, Fumery M, Singh AG, et al. Comparative risk of cardiovascular events with biologic and synthetic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis: a systematic review and meta-analysis. Arthritis Care Res (Hoboken). 2020;72(4):561–576. doi: 10.1002/acr.23875
  85. Ridker PM. From RESCUE to ZEUS: will interleukin-6 inhibition with ziltivekimab prove effective for cardiovascular event reduction? Cardiovasc Res. 2021;117(11):e138–e140. doi: 10.1093/cvr/cvab231

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2025 Eco-Vector


СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № ФС 77 - 71733 от 08.12.2017.